



(51) International Patent Classification:

A61K 9/48 (2006.01) A61J 3/00 (2006.01)  
A61K 31/78 (2006.01) A61K 47/32 (2006.01)  
A61K 47/42 (2017.01) A61K 47/58 (2017.01)  
A61J 3/07 (2006.01)

(21) International Application Number:

PCT/US2023/060631

(22) International Filing Date:

13 January 2023 (13.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/299,128 13 January 2022 (13.01.2022) US

(71) Applicant: **AMRYT ENDO, INC.** [US/US]; 160 Federal Street, 21st Floor, Boston, Massachusetts 02110 (US).

(72) Inventors: **CARON, David**; c/o Amryt Endo, Inc., 160 Federal Street, 21st Floor, Boston, Massachusetts 02110 (US). **LANDAU, Isaac**; c/o Amryt Endo, Inc., 160 Federal Street, 21st Floor, Boston, Massachusetts 02110 (US).

(74) Agent: **BROWN, Fraser et al.**; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):


AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ORAL DOSAGE FORMS

FIG. 3



(57) Abstract: The present invention relates generally to encapsulated pharmaceutical compositions enabling improved oral delivery and methods of using such compositions.

[Continued on next page]

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*